Chengdu Tianyin files renewal application for High Tech Enterprise Status

Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that the operating subsidiary of TPI, Chengdu Tianyin Pharmaceutical ("Chengdu Tianyin"), has submitted the application for the renewal of its High Tech Enterprise Status at Chengdu, Sichuan Province of China.

Chengdu Tianyin is a wholly foreign-owned enterprise incorporated in the PRC and subject to PRC Foreign Enterprise Income Tax ("FEIT") Law. Chengdu Tianyin has been entitled to the preferential tax treatment for opening up its production facility in Western China in Sichuan Province. The applicable reduced preferential state enterprise income tax rate under this policy is 15% until December 31, 2010. If Chengdu Tianyin's High Tech Enterprise Status can be successfully renewed, it will reduce the current enterprise income tax to 15% for another three years from the beginning of 2011 calendar year.

The management will provide the progress update regarding the application process.

Source:

Tianyin Pharmaceutical Co., Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Patient-derived organoids: Transforming cancer research and personalized medicine